Monoclonal Antibody Biosimilars for Oncology Enter the European Market and their Future is Bright
On February 22, 2017, the European Commission (EC), following the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human... In DRG Blog/ February, 2017 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer - A Paradigm Shift.
The immune checkpoint inhibitor buzz began almost 3 years ago to the day, with the first presentation of Opdivo data from a Phase I trial, at the... In DRG Blog, Drug Watch/ June, 2015 Advancing the Treatment of TKI-refractory NSCLC
Non-small-cell lung cancer (NSCLC) is considered by many to be the poster child for personalized medicine in oncology. The approval of tyrosine... In DRG Blog, Drug Watch/ October, 2014 Avastin in Glioblastoma: A treatment breakthrough or the retelling of an old story
ASCO 2013 Impressions Presentations regarding the use of Avastin in glioblastoma (GBM) were prominent in the Central Nervous System Cancer and... In DRG Blog, Drug Watch/ June, 2013